
Date: 2021-03-29	$\sim$	, /,		
Your Name: Shangyu Liu	Mangan	Livi.		
Manuscript Title: <u>Machine Learni</u>	ng-Based Long-Term Ou	tcome Prediction i	in Patients Under	rgoing Percutaneous
Coronary Intervention				
Manuscript number (if known):				

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
		Time frame: pas	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	



		. /
5	Payment or honoraria for	<u></u> <b>≻</b> None
	lectures, presentations,	
:	speakers bureaus, manuscript writing or educational events	
6	Payment for expert testimony	None
7	Support for attending meetings and/or travel	∠_None
	Amus 1000 Amus 1000 Amus 1000	[20] - 교통의 기계 [20] - 관련의 관통의 교통의 교통의 공급의 기계
8	Patents planned, issued or pending	None
9	Participation on a Data	✓ None
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None
11	Stock or stock options	None
	· ·	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other	None
	services	
13	Other financial or non-	X None
	financial interests	
L	· · · · · · · · · · · · · · · · · · ·	
L.,		

None.			
	 	,	

Please place an "X" next to the following statement to indicate your agreement:



Date: 2021-03-29	$\sim$		
Your Name: Shengwen Yang	Sherg	Wen lange	
Manuscript Title: Machine Learning-Bas	ed Long-Term C	outcome Prediction in Pa	atients Undergoing Percutaneous
Coronary Intervention			
Manuscript number (if known):			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or	None	
6	educational events Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

None.	Section 1	 

Please place an "X" next to the following statement to indicate your agreement:

Date: <u>2021-03-29</u>			
Your Name: Anlu Xing	<i></i>	nlu Ning	
Manuscript Title: Machine Learning-Based Long-1	Term Out	come Prediction	in Patients Undergoing Percutaneous
Coronary Intervention			
Manuscript number (if known):			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

	14 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

		\( \)	
5	Payment or honoraria for	<u>None</u>	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
<u> </u>	educational events	X	
6	Payment for expert testimony	/None	
7	Support for attending	None	
	meetings and/or travel		
		446	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role in other board, society,	None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	<u>X</u> None	
	사 1. 정말성 기 교육하다		
		100	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
13	services Other financial or non-	V Name	
12	financial interests	None	
	iniancial interests		
	·	· 기본 : 기본	

None.	

Please place an "X" next to the following statement to indicate your agreement:



Date: 2021-03-29

	ır Name: <u>Lihui Zheng</u>		ena
Ma	nuscript Title: <u>Machine Lear</u>	ning-Based Long-Term Out	come Prediction in Patients Undergoing Percutaneous
Cor	onary Intervention		
Ma	nuscript number (if known):		
rela par to t rela	ited to the content of your nation whose interests may be ransparency and does not not interest, it	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias. t is preferable that you do	
	following questions apply t nuscript only.	o the author's relationship	s/activities/interests as they relate to the <u>current</u>
to t med In it	he epidemiology of hyperte dication, even if that medica	nsion, you should declare a ition is not mentioned in th port for the work reported	efined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive ne manuscript.  in this manuscript without time limit. For all other items,
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	X_None	

None

Consulting fees

5	Payment or honoraria for	X_None
	lectures, presentations,	
	speakers bureaus, manuscript writing or	
	educational events	
6	Payment for expert testimony	None
7	Support for attending meetings and/or travel	<u>Y</u> None
8	Patents planned, issued or pending	None
9	Participation on a Data	X
9	Safety Monitoring Board or	None
	Advisory Board	
10	Leadership or fiduciary role	None
	in other board, society,	
	committee or advocacy	
11	group, paid or unpaid Stock or stock options	X None
	Stock of Stock options	None
12	Receipt of equipment,	None
	materials, drugs, medical writing, gifts or other	
	services	
13	Other financial or non-	None
	financial interests	

None.

Please place an "X" next to the following statement to indicate your agreement:



Dat	e:2021-03-29		. 0
You	r Name: <u>Lishui Shen</u>		ichini Shend
Ma	nuscript Title: <u>Machine Lear</u>	ning-Based Long-Term Out	tcome Prediction in Patients Undergoing Percutaneous
Cor	onary Intervention	_	7
Mai	nuscript number (if known):		
rela part to t	ited to the content of your r ties whose interests may be	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias.	relationships/activities/interests listed below that are ins any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a
The		•	os/activities/interests as they relate to the <u>current</u>
to t	author's relationships/activ he epidemiology of hyperte dication, even if that medica	nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive he manuscript.
	em #1 below, report all sup time frame for disclosure is	the past 36 months.	in this manuscript without time limit. For all other items,
	· ·	Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate none (add rows as	institution)
		needed)	
		Time frame: Since the initia	I planning of the work
1	All support for the present	None	
-	manuscript (e.g., funding,	7.10110	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	t 36 months
2	Grants or contracts from	X None	
_	any entity (if not indicated	1	
	in item #1 above).		
3	Royalties or licenses	X None	

X\_None

4

Consulting fees



		V	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events	44-1	
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
	meetings and/or traver		
		ting to the state of the state	
		11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11.500 11	
8	Patents planned, issued or pending	X_None	
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role in other board, society, committee or advocacy	_X_None	
	group, paid or unpaid		
11	Stock or stock options	✓ None	
	Stock of Stock opposis	None	
*			
12	Receipt of equipment,	<b>★</b> None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	None	
	financial interests		

None.		****	

Please place an "X" next to the following statement to indicate your agreement:

Date:_	2021-03-29	9	)			
Your N	ame:	Bin Tu	V	in	M	
Manus	cript Title: I	<b>Machine Learning</b>	-Bas	ed Long-T	erm	<b>Outcome Prediction in Patients Undergoing Percutaneous</b>
Corona	ry Interven	tion				
Manus	cript numbe	er (if known):				

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	l planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
		Time frame: past	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	



5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

None.			11

Please place an "X" next to the following statement to indicate your agreement:



Date:_	2021-03-	29						
Your N		Yan Yao	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \					
Manus	script Title	: <u>Machine Learnir</u>	g-Based Long T	erm Curco	me Predictio	n in Patient	s Undergoing	 Percutaneous
	ary Interve			t				
Manus	script num	ber (if known):						

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	



F			
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	None	A Company of the Company of the Appendix of the Company of the Com
	testimony		
7	Support for attending meetings and/or travel	None	
	meetings and/or traver		
			The second secon
8	Patents planned, issued or	None	
	pending		
9	Doubling and Dob	X 11-	5-2-a.
9	Participation on a Data Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role	<u></u> None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	X. None	
11	Stock of Stock options	1 None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	✓ None	
	financial interests	1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m / 1 m /	

None.		

Please place an "X" next to the following statement to indicate your agreement:

